Aladdin Healthcare Technologies SE launches, alongside an Indian based partner, its Health Risk Assessment Tool (HRA) for diabetes, cardiovascular health and COVID-19 to the India based employees of two global corporations Airbus (India) and Saregama (India). OurHealthMate (OHM) has introduced the 'Health Risk Assessment Tool' developed by Aladdin to its clients Airbus in India and Saregama India Ltd. as a part of the HealthCare management services portfolio for 2020-21. OHM is an accredited doctor-patient platform for clinical searches in India working with over 2,000 healthcare institutions and serving 30,000 doctors and over 32 million patients in its network. The Aladdin Health Risk Assessment (HRA) tool combines artificial intelligence (AI) with risk analytics and will be available as both a web and mobile application. With this technological intervention, Airbus and Saregama will be able to have a better employee insight, coupled with a process that includes biometric testing to assess its workplace's health insights and risks, as well as habits. Aladdin is delivering a new generation of healthcare management technology to the Indian market. At the same time, the AI suggests suitable further care measures and gives lifestyle advice to the employees directly. The partnership between Aladdin and OHM provides a whole suite of healthcare services to all the employees of Airbus and Saregama in India. The services include Health Risk Assessment, Physical healthcare services including diagnostics, Counsellor services, etc. With the HRA tool in use, together it assists in taking informed decisions on future healthcare management initiatives for its employees as well as significant cost savings by directing the budgeting process in the right direction. Aladdin's health risk assessment application currently includes diabetes, cardiovascular health with COVID-19 to follow. The application has been integrated into OHMs platform which consists of 40 large corporate employee healthcare schemes. Airbus and Saregama are the first with more to follow.